Lack of association between pro-inflammatory cytokine (IL-6, IL-8 and TNF-α) gene polymorphisms and Graves' disease

被引:25
作者
Chen, RH
Chen, WC
Wang, TY
Tsai, CH
Tsai, FJ
机构
[1] Taichung Healthcare Management Univ, Taichung, Taiwan
[2] China Med Univ, China Med Univ Hosp, Dept Med, Taichung, Taiwan
[3] China Med Univ, China Med Univ Hosp, Dept Urol, Taichung, Taiwan
[4] China Med Univ, China Med Univ Hosp, Dept Med Genet, Taichung, Taiwan
[5] China Med Univ, China Med Univ Hosp, Dept Pediat, Taichung, Taiwan
关键词
D O I
10.1111/j.1744-313X.2005.00536.x
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Graves' disease (GD) is a common, autoimmune disease involving the thyroid gland, and it has been previously suggested that pro-inflammatory cytokines are involved in the disease's pathogenesis. The aim of this study was to test whether the interleukin (IL)-6 gene promoter region, or tumour necrosis factor (TNF)-alpha or IL-8 gene 3'-untranslated region (3'-UTR) polymorphisms could provide useful genetic markers for an individual's susceptibility to GD. A normal control group of 60 healthy people and 95 patients featuring GD were examined. Polymerase chain reaction (PCR)-based restriction analysis was performed for the three gene polymorphisms using endonucleases BsrBI, NcoI and ApaLI, respectively. We found no significant difference between the frequencies of genotype and allelic variants for the IL-6 gene promoter (-572 G/C), the TNF-alpha gene promoter (-308 A/G) and the IL-8 gene 3'-UTR (2767 A/G) for GD patients and for normal controls. Cytokines are a large group of proteins that may elicit multiple effects upon immunological reactions. It still appears to be very worthwhile to continue to aggressively search for cytokine gene polymorphisms in order to predict the development of such disease.
引用
收藏
页码:343 / 347
页数:5
相关论文
共 26 条
[1]  
Amoli MM, 2002, J RHEUMATOL, V29, P2367
[2]   Expression of tumour necrosis factor-alpha (TNF-alpha) mRNA and protein in pathological thyroid tissue and carcinoma cell lines [J].
Aust, G ;
Heuer, M ;
Laue, S ;
Lehmann, I ;
Hofmann, A ;
Heldin, NE ;
Scherbaum, WA .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1996, 105 (01) :148-154
[3]   Chemokines in pathology and medicine [J].
Baggiolini, M .
JOURNAL OF INTERNAL MEDICINE, 2001, 250 (02) :91-104
[4]   ASSOCIATION OF GRAVES-DISEASE WITH AN ALLELE OF THE INTERLEUKIN-1 RECEPTOR ANTAGONIST GENE [J].
BLAKEMORE, AIF ;
WATSON, PF ;
WEETMAN, AP ;
DUFF, GW .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (01) :111-115
[5]  
BOTTAZZO GF, 1983, LANCET, V2, P1115
[6]  
CASEY ML, 2000, TXB ENDOCRINE PHYSL, P90
[7]   Association of an allelic variant of interleukin-6 with subclinical carotid atherosclerosis in an Australian community population [J].
Chapman, CML ;
Beilby, JP ;
Humphries, SE ;
Palmer, LJ ;
Thompson, PL ;
Hung, J .
EUROPEAN HEART JOURNAL, 2003, 24 (16) :1494-1499
[8]   Interleukin-1-β gene, but not the interleukin-1 receptor antagonist gene, is associated with Graves' disease [J].
Chen, RH ;
Chen, WC ;
Chang, CT ;
Tsai, CH ;
Tsai, FJ .
JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2005, 19 (04) :133-138
[9]   Association of interleukin-6 promoter variant with bone mineral density in pre-menopausal women [J].
Chung, HW ;
Seo, JS ;
Hur, SE ;
Kim, HL ;
Kim, JY ;
Jung, JH ;
Kim, LH ;
Park, BL ;
Shin, HD .
JOURNAL OF HUMAN GENETICS, 2003, 48 (05) :243-248
[10]  
Corrales JJ, 1997, CYTOMETRY, V30, P118, DOI 10.1002/(SICI)1097-0320(19970615)30:3<118::AID-CYTO2>3.0.CO